Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 13, 2013, Pages 2744-2752

  Hourigan, Suchitra K ^a   Chirumamilla, Sankar R ^b   Ross, Tracy ^c   Golub, Jonathan E ^a   Rabizadeh, Shervin ^d   Saeed, Shehzad A ^e   Elson, Charles O ^f   Kelly, Ciaran P ^g   Carroll, Karen C ^a   Oliva Hemker, Maria ^a   Sears, Cynthia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f University of Alabama at Birmingham   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clostridium difficile; IBD; Pediatrics

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; CLOSTRIDIUM DIFFICILE TOXIN A; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CHILD; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PEDIATRICS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS; SCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84893724752     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000435434.53871.36     Document Type: Article

References (38)

1. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8:17-26.
2. Sammons JS, Toltzis P. Recent trends in the epidemiology and treatment of C. difficile infection in children. Curr Opin Pediatr. 2013;25:116-121.
3. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1-15.
4. Pohl JF. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr. 2012;24:627-631.
5. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339-344.
6. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983.
7. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
8. Reddy SS, Brandt LJ. Clostridium difficile Infection and Inflammatory Bowel Disease. J Clin Gastroenterol. 2013;47:666-671.
9. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104:1162-1169.
10. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010;51:2-7.
11. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35-40.
12. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
13. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
14. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1720-1728.
15. Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18: 1340-1355.
16. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
17. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-432.
18. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial realtime PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol. 2009;47:373-378.
19. Rousseau C, Levenez F, Fouqueray C, et al. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol. 2011;49:858-865.
20. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435-438.
21. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-13785.
22. Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol. 2013;6:53-68.
23. Lamousé-Smith ES, Weber S, Rossi RF, et al. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without IBD. J Pediatr Gastroenterol Nutr. 2013;57: 293-297.
24. Mezoff E, Mann EA, Hart KW, et al. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population. J Pediatr Gastroenterol Nutr. 2011;52:437-441.
25. Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr. 2009;154: 854-858.
26. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:50-55.
27. Wultanska D, Banaszkiewicz A, Radzikowski A, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis. 2010;29:1265-1270.
28. Banaszkiewicz A, Kowalska-Duplaga K, Pytrus T, et al. Clostridium difficile infection in newly diagnosed pediatric patients with inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis. 2012;18: 844-848.
29. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5: 345-351.
30. Centers for Disease Control and Prevention. Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012; 61:157-162.
31. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365: 1693-1703.
32. Haapamäki J, Tanskanen A, Roine RP, et al. Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. Scand J Gastroenterol. 2013;48:42-50.
33. Selvaraju SB, Gripka M, Estes K, et al. Detection of toxigenic Clostridium difficile in pediatric stool samples: an evaluation of Quik Check Complete Antigen assay, BD GeneOhm Cdiff PCR, and ProGastro Cd PCR assays. Diagn Microbiol Infect Dis. 2011;71:224-229.
34. Shakir FA, Ali T, Bigham AC, et al. Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2012;8:313-317.
35. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
36. Shim JK, Johnson S, Samore MH, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998;351:633-636.
37. Cohen SH, Gerding DN, Johnson S, et al Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
38. Schutze GE, Willoughby RE; Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics. 2013;131:196-200.